Poster 409: Incomplete Paraplegia Caused by a T7/T8 Subdural Hematoma in a Middle-Aged Man Started on Warfarin for New Onset Atrial Fibrillation: A Case Report

PM&R ◽  
2010 ◽  
Vol 2 ◽  
pp. S179-S179
Author(s):  
Bradley Benson ◽  
Michael Acuff
2016 ◽  
Vol 91 (12) ◽  
pp. 1769-1777 ◽  
Author(s):  
Avi Sabbag ◽  
Anat Berkovitch ◽  
Yechezkel Sidi ◽  
Shaye Kivity ◽  
Sagit Ben Zekry ◽  
...  

2015 ◽  
Vol 70 (2) ◽  
pp. 247-247
Author(s):  
Priyank Shah ◽  
Vipin Mittal ◽  
Fadi Alattar ◽  
Donna Konlian ◽  
Aderemi Soyombo ◽  
...  

2016 ◽  
Vol 173 ◽  
pp. 41-48 ◽  
Author(s):  
Anat Berkovitch ◽  
Shaye Kivity ◽  
Robert Klempfner ◽  
Shlomo Segev ◽  
Assi Milwidsky ◽  
...  

2018 ◽  
Vol 82 (7) ◽  
pp. 1763-1769 ◽  
Author(s):  
Yong-Giun Kim ◽  
Kee-Joon Choi ◽  
Seungbong Han ◽  
Ki Won Hwang ◽  
Chang Hee Kwon ◽  
...  

2016 ◽  
Vol 67 (13) ◽  
pp. 853
Author(s):  
Avi Sabbag ◽  
Anat Berkovitch ◽  
Yechezkel Sidi ◽  
Shaye Kivity ◽  
Roy Binart ◽  
...  

2020 ◽  
Vol 21 ◽  
Author(s):  
Toby N. Weingarten ◽  
Hiroshi Morimatsu ◽  
Juan Fiorda-Diaz ◽  
Sergio D. Bergese ◽  
Makiko Ariyoshi ◽  
...  

2019 ◽  
Vol 26 (18) ◽  
pp. 1987-1997 ◽  
Author(s):  
Giulia Renda ◽  
Fabrizio Ricci ◽  
Giuseppe Patti ◽  
Nay Aung ◽  
Steffen E Petersen ◽  
...  

Aims The CHA2DS2VASc score is used to evaluate the risk of thromboembolic events in patients with non-valvular atrial fibrillation. We assessed the prognostic yield of CHA2DS2VASc for new-onset atrial fibrillation, cardiovascular morbidity and mortality in a non-atrial fibrillation population. Methods We analysed a population-based cohort of 22,179 middle-aged individuals with ( n = 3542) and without ( n = 18,367) a history of atrial fibrillation; we grouped the population into five CHA2DS2VASc strata (0–1–2–3–≥4), and compared the risk of major adverse cerebro-cardiovascular events and mortality. Furthermore, we analysed the annual incidence of atrial fibrillation across different CHA2DS2VASc strata. Results Over a median follow-up of 15 years, 1572 patients (6.9%) had ischaemic strokes, 2162 (9.5%) coronary events and 5899 (26%) died. The cumulative incidence of ischaemic stroke in CHA2DS2VASc ≥ 4 subjects without atrial fibrillation was similar to patients with atrial fibrillation and CHA2DS2VASc 2, with a 10-year crude incidence rate of 0.91 (95% confidence interval (CI) 0.68–1.19) and 1.13 (95% CI 0.93–1.36) ischaemic strokes per 100 patient-years, respectively. CHA2DS2VASc in a non-atrial fibrillation population showed higher predictive accuracy for ischaemic stroke compared with an atrial fibrillation population (area under the curve 0.60 vs. 0.56; P = 0.001). In multivariable Cox regression analysis, CHA2DS2VASc ≥ 2 was an independent predictor of all-cause death (adjusted hazard ratio (aHR) 2.58; 95% CI 2.42–2.76), cardiovascular death (aHR 3.40; 95% CI 2.98–3.89), ischaemic stroke (aHR 2.20; 95% CI 1.92–2.53) and coronary events (aHR 1.83; 95% CI 1.63–2.04). The cumulative incidence of atrial fibrillation was greater with increasing CHA2DS2VASc strata, with an absolute annual incidence of more than 2% per year if CHA2DS2VASc ≥ 4. Conclusion The CHA2DS2VASc score is a sensitive tool for predicting new-onset atrial fibrillation and adverse outcomes in subjects both with and without atrial fibrillation.


Sign in / Sign up

Export Citation Format

Share Document